

1247

POSTER

# Phase I, Pharmacokinetics (PK), Pharmacodynamic (PD) Study of Lapatinib (L) in Combination With Sorafenib (S) in Patients With Advanced Refractory Solid Tumours

M. Simonelli<sup>1</sup>, P.A. Zucali<sup>1</sup>, R. De Sanctis<sup>1</sup>, E. Lorenzi<sup>1</sup>, F. De Vincenzo<sup>1</sup>, L. Rimassa<sup>1</sup>, M.C. Tronconi<sup>1</sup>, M. Zuradelli<sup>1</sup>, L. Giordano<sup>1</sup>, A. Santoro<sup>1</sup>.  
<sup>1</sup>Humanitas Cancer Center, Oncology and Hematology, Rozzano (Milano), Italy

**Background:** A large body of experimental evidence supports the relevance of ERBB-dependent and VEGF-dependent pathways in cancer pathogenesis and progression, their functional links and implications in acquired resistance to targeted therapies. Combined targeting of ERBB receptors and VEGF-dependent signaling pathways has proven to be a successful strategy in preclinical studies. L is a dual HER2/EGFR tyrosine kinase inhibitor, S is an oral multikinase inhibitor (VEGFR-2,3, PDGFR- $\beta$ , Flt-3, Raf-1 and c-KIT). We conducted a phase I dose-escalation study to assess the maximum tolerated dose (MTD), safety/tolerability, PK, PD and preliminary antitumour activity of the combination of these two agents (NCT00984425).

**Methods:** Patients (pts) with advanced malignancies refractory to standard therapy were eligible. A traditional 3+3 dose escalation schema was employed. Dose levels (DL) were 1) L 750 mg + S 200 mg BID; 2) L 1000 mg + S 200 mg BID; 3) L 1000 mg + S 400 mg BID; 4) L 1250 mg + S 400 mg BID. L and S were given together on a continuous schedule with a 28-day cycle. Once the MTD has been determined, additional 9 patients were enrolled in the PK part of the study and received L alone during a "running-in" period for two weeks before starting with the combined schedule.

**Results:** 30 pretreated pts (median 3 previous lines, range 1–6) were enrolled, M/F: 19/11, median age: 65 yrs (25–76), PS: 0/1 = 15/15. DLTs were observed in 2 pts, one at DL 2 [grade (G) 3 fatigue] and one at DL 3 (G3 rash). The MTD was reached at DL4. The most common toxicities were fatigue (64%), diarrhea (61%), anemia (61%), rash (43%), and hand-foot syndrome (29%). G3 treatment-related AEs were reported in 9 pts (32%) (anemia, fatigue, diarrhea, hyponatremia, hypokalemia, rash, LDH and phosphatase alkaline increase) and G4 AST/ALT increase in one pt. Pts received a median of 2 cycles (1–14). Among 28 evaluable pts (3 ongoing), 1 had CR (thymic cancer), 4 PR (prostate, colorectal, breast, and thymic cancers) and 12 SD (4 colorectal, 3 gastric, 2 pancreatic, 1 prostate, 1 breast, 1 bladder cancers), with a DCR of 61%. Median clinical benefit duration was 8 wks (2–43). Preliminary PK data suggest that S may alter L concentrations.

**Conclusions:** The combination of L + S is safe and well tolerated. L 1250 mg + S 400 mg BID is the recommended dose for phase II trials. Preliminary evidence of anticancer activity has been observed. Updated clinical and biological data will be presented at the meeting.

1248

POSTER

# A Phase I Study Evaluating GDC-0941, a Pan-phosphoinositide-3 Kinase (PI3K) Inhibitor, in Patients (pts) With Advanced Solid Tumours, Multiple Myeloma, and PIK3CA Mutant (mt) Tumours

S. Banerjee<sup>1</sup>, R. Baird<sup>1</sup>, B. Basu<sup>1</sup>, K. Shah<sup>1</sup>, N. Tunariu<sup>2</sup>, V. Moreno Garcia<sup>1</sup>, J. Corral<sup>1</sup>, K. Mazina<sup>3</sup>, G. Levy<sup>3</sup>, J. de Bono<sup>1</sup>. <sup>1</sup>The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Drug Development Unit, Sutton, <sup>2</sup>The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Drug Development Unit and Clinical MRI Unit, Sutton, United Kingdom; <sup>3</sup>Genentech Inc, Genentech Research and Early Development, San Francisco, USA

**Background:** The PI3K-PTEN-AKT signaling pathway is deregulated in a wide variety of cancers. GDC-0941 is a potent and selective inhibitor of class I PI3K under evaluation in this phase I study of pts with refractory cancer.

**Material and Methods:** A 2-stage phase I study (GDC4254g) of single-agent GDC-0941 was initiated in pts with refractory cancer and ECOG performance status of 0–1. Stage 1 utilized a 3+3 escalation design to evaluate the maximum tolerated dose (MTD) in pts with advanced solid tumours. Stage 2 is an expansion phase including pts with multiple myeloma, PIK3CA mt tumours, and tumours evaluable by magnetic resonance imaging (MRI) methods. Single-dose and steady state pharmacokinetics (PK) and pharmacodynamics (PD) of oral GDC-0941 were evaluated. GDC-0941 is administered QD on a 21/28- or 28/28-day schedule. Objectives include: evaluating pS6 in paired tumour biopsies and pAKT in platelet rich plasma (PRP), evaluating the use of imaging modalities (FDG-PET and functional MRI studies), and correlating clinical activity with PIK3CA mt status and PTEN expression in tumour tissue.

**Results:** Forty-three pts have been enrolled in 12 cohorts (15–450 mg QD). Drug-related adverse events (AEs) reported in  $\geq 10\%$  of pts were nausea,

fatigue, diarrhea, vomiting, rash, dysgeusia, and decreased appetite. The MTD was exceeded at 450 mg QD on a 21/28-day dose schedule with dose-limiting toxicities of grade (g) 3 maculopapular rash in 2 pts. Other drug-related AEs  $\geq g3$  have been g3 fatigue, g3 neutropenia, and g4 hyperglycemia. GDC-0941 displays dose-proportional PK. Decreased levels of pAKT in PRP correlated with GDC-0941 plasma concentrations. Signs of clinical activity include a partial response (49% decrease in target lesions) by RECIST in a pt with melanoma (V600E RAF mt) treated at 330 mg for 9.5 months (mo); a small bowel GIST (cKIT exon 9 mt) pt treated at 450 mg for 7.2 mo with 49% decrease by FDG-PET and 75% decrease in pS6 IHC staining in paired tumour biopsies; and an ovarian cancer (PTEN negative) pt treated at 100 mg on study for ~5 mo with 30% decrease by FDG-PET, 56% decrease in pS6 staining in paired biopsies, and 80% decrease in CA-125.

**Conclusions:** GDC-0941 is generally well tolerated below 450 mg QD with signs of clinical activity. Decreases in pAKT levels in PRP and in pS6 staining in paired tumour biopsies are consistent with downstream modulation of the PI3K pathway. Final determination of the recommended phase II dose and schedule is ongoing.

1249

POSTER

# Cutaneous Manifestations of Selumetinib, a New MEK Inhibitor

M. Thomas<sup>1</sup>, C. Mateus<sup>1</sup>, J. Wechsler<sup>2</sup>, G. Tomasic<sup>3</sup>, B. Dreno<sup>4</sup>, P. Saiag<sup>5</sup>, J.P. Arnault<sup>1</sup>, L. Maksimovic<sup>1</sup>, E. Routier<sup>1</sup>, C. Robert<sup>1</sup>.

<sup>1</sup>Institut Gustave Roussy, Dermatology, Villejuif, <sup>2</sup>Henri Mondor Hospital, Dermatology, Créteil, <sup>3</sup>Institut Gustave Roussy, Pathology, Villejuif, <sup>4</sup>Hôtel Dieu, Dermatology, Nantes, <sup>5</sup>Ambroise Paré Hospital, Dermatology, Boulogne, France

**Background:** Selumetinib is a potent oral MEK1/2 inhibitor tested in patients with melanomas, pancreatic and non-small cell lung cancers.

**Methods:** A retrospective study of the skin manifestations of all patients treated with selumetinib in France in a phase II study evaluating selumetinib versus temozolomide (N = 19).

**Results:** All patients except for one (18/19; 95%) presented with at least one cutaneous side effect. The spectrum of skin manifestations is close to that observed with EGFR inhibitors: follicular papulopustular rash, xerosis, hair and nail changes. Two additional symptoms, edema and erysipeloid reactions, were observed that could be imputable to selumetinib.

**Conclusion:** Skin manifestations induced by selumetinib are extremely frequent with a partial overlap with those observed with anti-EGFR agents.

1250

POSTER

# Phase I Study of Pazopanib(P) Monotherapy and Combined With Lapatinib(L) in Japanese Patients(pts) With Solid Tumours (VEG109693)

K. Yamashita<sup>1</sup>, Y. Sunakawa<sup>1</sup>, H. Ishida<sup>1</sup>, T. Yokoyama<sup>1</sup>, A. Takekura<sup>2</sup>, K. Katsura<sup>2</sup>, Y. Ando<sup>3</sup>, Y. Sasaki<sup>1</sup>. <sup>1</sup>Saitama Medical University International Medical Center, Department of Medical Oncology, Saitama, <sup>2</sup>GlaxoSmithKline K.K., Development & Medical Affairs Division, Tokyo, <sup>3</sup>Nagoya University Hospital, Department of Clinical Oncology and Chemotherapy, Nagoya, Japan

**Background:** Pazopanib (Votrient®) is an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-kit. Lapatinib (Tykerb®/Tyverb®) is a potent inhibitor of ErbB1 and ErbB2. Several lines of evidence support the use of combined inhibition of VEGFR and ErbB in the treatment of certain malignancies. The present study was initiated to confirm recommended dose of P monotherapy and combination with L and to determine pharmacokinetics (PK) in Japanese pts.

**Methods:** Pts with solid tumours were enrolled. In part A (P dose escalation), dose levels were 1) 400 mg/day on day1 followed by 800 mg/day (400 → 800), 2) 800 → 800 and 3) 1000 → 1000. In part B (P+L), dose levels were 1) 400/1000 mg/day (P/L), 2) 400/1500, 3) 800/1000 and 4. 600/1250. At Part B level 4, pts received P600 or L1250 alone from day 1 to 15. From day 16, P600 in combination with L1250 was administered. DLTs and safety were evaluated in each part. PK data were obtained on days 1 and 22 of part A and days 15 and 37 of part B level 4. (NCT00516672; Trial Sponsor: GSK; Status: Concluded)

**Results:** No DLT was observed in part A and B. In part A, hypertension, diarrhea, rash, AST, lipase elevation and neutropenia were most frequent AEs, the majority of which were of grade 1/2. In part B, hypertension, rash, nausea, dysgeusia, anorexia, fatigue and TSH elevation were commonly observed, diarrhea was reported in all pts, the majority of which were of grade 1/2. AUC<sub>0-24</sub> (μg·hr/mL) after single dose of P on day1 is shown in the table. The relation between dose and AUC was not linear and there is no difference between P800 and P1000. AUC<sub>0-24</sub> on day 22 of P shown

in table below indicated the accumulation of P. In combined administration of P600 and L1250, no PK interaction was observed. Long term disease control of partial response and stable disease over three months was observed in 3 of 13 pts in part A and 11 of 17 pts in part B.

**Conclusions:** P was well tolerated and safe in Japanese pts. A monotherapy dose of 800 mg/day was recommended for Japanese pts. Any combined dose levels of P and L were recommendable.

	Dose (mg)	N	AUC <sub>0-24</sub> (µg·hr/mL), GeoMean [95% CI]			
			day 1	day 15	day 22	day 37
Part A (P)						
level 1	400 → 800	3	402.3 (N = 3) [260.2, 621.9]	—	739.5 (N = 8) [514.5, 1062.8]	—
level 2	800 → 800	7	324.6 (N = 7) [173.0, 608.9]	—	739.5 (N = 8) [514.5, 1062.8]	—
level 3	1000 → 1000	3	305.0 (N = 3) [26.2, 3548.6]	—	759.5 (N = 3) [177.7, 3246.1]	—
Part B (P/L)						
level 1	400/1000	3	—	—	—	—
level 2	400/1500	3	—	—	—	—
level 3	800/1000	4	—	—	—	—
level 4	600/1250	7	—	—	—	—
		P	—	1331.4 (N = 3) [946.0, 1873.9]	—	1188.8 (N = 6) [815.3, 1733.3]
		L	—	28.4 (N = 3) [9.7, 83.1]	—	29.5 (N = 6) [19.4, 44.9]

## 1251

## POSTER

### Preclinical and Clinical Development of 4SC-203 – a Novel Multi-target Kinase Inhibitor

R. Krauss<sup>1</sup>, F. Wagner<sup>2</sup>, R. Doblhofer<sup>1</sup>, B. Dietrich<sup>1</sup>, J. Ehler<sup>3</sup>, M.H.G. Kubbutat<sup>3</sup>, A. Lingnau<sup>3</sup>, F. Totzke<sup>3</sup>, C. Schächtele<sup>3</sup>, B. Hentsch<sup>1</sup>.  
<sup>1</sup>4SC AG, Development, Planegg, <sup>2</sup>Charité Research Organisation GmbH, Berlin, <sup>3</sup>ProQinase GmbH, Freiburg, Germany

4SC-203 is a novel small molecule selective-spectrum kinase inhibitor of the benzothiazole chemical class displaying a unique selectivity profile against FLT3, FLT3 mutants, AXL, ALK, FAK, VEGF-R2, and TRK receptors in both *in vitro* studies with an inhibitory activity on cell line growth in the low nanomolar range. Furthermore, in preclinical studies 4SC-203 has shown a pronounced anti-tumour activity in acute myeloid leukaemia (AML)-related *in vivo* models. In a first in man study in healthy volunteers 4SC-203 proved to be well tolerated over the whole concentration range investigated and to have a favourable pharmacokinetic profile.

FLT3 represents an attractive therapeutic target in AML, as this kinase is frequently over-expressed or mutated in patients with this disease, which causes uncontrolled cell growth. Activating FLT3 mutations can be identified in approximately one third of these patients, a subgroup associated with a dismal prognosis due to a high relapse rate, with currently no satisfactory treatment option available. Beyond FLT3, 4SC-203 has been shown to inhibit kinases involved in angiogenesis (EPHA, EPHB and VEGF receptors which are responsible for stimulating the cellular responses required for blood vessel formation) and metastasis (e.g. AXL and FAK). 4SC-203 was co-developed with ProQinase GmbH, Freiburg, Germany (www.proqinase.com).

In a randomised, double-blind, placebo-controlled, Phase I dose escalation study (ClinicalTrials.gov Identifier: NCT01054937) the safety, tolerability, and pharmacokinetics of 4SC-203 was assessed in 60 healthy, male volunteers aged 20 to 46 years. Cohorts of eight subjects each, randomised in a 6:2 ratio (active:placebo), received ascending single intravenous doses of the compound. The dose range comprised 0.041 to 2.5 mg/kg body weight.

Treatment in all cohorts was well tolerated with headache and reactions on the injection site being the most common side effects. There was no indication on target organ toxicity. No relevant changes in laboratory parameters, vital signs and ECG were apparent during the course of the study. 4SC-203 shows a favourable PK-profile with dose proportionality for both AUC and C<sub>max</sub>. Geometric mean terminal half-lives up to about 30 h were observed in the high dose groups.

Preclinical and final Phase I clinical data of 4SC-203 will be presented.

## 1252

## POSTER

### First Report of the Safety, Tolerability, and Pharmacokinetics of Saracatinib (AZD0530) in Japanese Patients With Advanced Solid Tumours

Y. Onozawa<sup>1</sup>, Y. Fujisaka<sup>2</sup>, H. Yasui<sup>1</sup>, T. Kurata<sup>3</sup>, K. Yamazaki<sup>1</sup>, I. Goto<sup>2</sup>, N. Machida<sup>1</sup>, J. Watanabe<sup>4</sup>, X. Shi<sup>5</sup>, N. Boku<sup>1</sup>.  
<sup>1</sup>Shizuoka Cancer Center, Division of Gastrointestinal Oncology, Shizuoka, <sup>2</sup>Osaka Medical College, First Department of Internal Medicine, Osaka, <sup>3</sup>Osaka Medical College, Chemotherapy Center, Osaka, <sup>4</sup>Shizuoka Cancer Center, Division of Female Medicine, Shizuoka, <sup>5</sup>AstraZeneca, Research and Development, Osaka, Japan

**Background:** Saracatinib is a selective, oral Src inhibitor that has demonstrated antitumour activity in patients with advanced solid tumours. This open-label, multicentre, dose-escalation, Phase I study evaluated the safety and tolerability of saracatinib in Japanese patients. Study sponsored by AstraZeneca; clinicaltrials.gov NCT00704366.

**Methods:** Eligible patients received saracatinib continuous once-daily oral dosing 7 days after a single dose in ascending dose cohorts until dose-limiting toxicity (DLT) or disease progression. DLT was defined as grade 4 haematological toxicity, grade 3/4 febrile neutropenia or any other grade 3/4 toxicity which, in the opinion of the investigator, was related to saracatinib in the period from the single dose up to 21 days of continuous dosing. Pharmacokinetics and preliminary efficacy were also evaluated. Adverse events (AEs) were evaluated according to CTCAE v3.0.

**Results:** Twelve patients (median age 57 years [range 38–78]; male: n = 7; PS 0/1: n = 5/7) received saracatinib doses of 50 mg (n = 3), 125 mg (n = 6), or 175 mg (n = 3). Tumour types included colorectal (n = 4), lung (n = 4), breast, oesophagus, stomach, and ovary (n = 1 each). Median number of prior chemotherapy regimens was 3 (range 1–10). The median duration of exposure was 65, 44, and 16 days in the 50, 125, and 175 mg groups, respectively. The most common AEs were diarrhoea (67%), nausea (67%), decreased appetite (58%), lymphopenia (50%) and pyrexia (50%). The most common AEs of grade ≥ 3 were leukopenia, lymphopenia, neutropenia, and haemoglobin decreased (all 17%). DLTs occurred in two patients, both in the 175 mg group: grade 3 AST increased associated with grade 2 ALT increase, grade 3 GGT increased (n = 1); and grade 3 hypoxia (n = 1). Following a single dose, saracatinib median t<sub>max</sub> across the doses was 2–4 hours, and thereafter plasma concentrations declined in a biphasic manner, with mean terminal t<sub>1/2</sub> of approximately 45 hours. Steady-state exposure was generally achieved 10–14 days after initiation of continuous dosing. Saracatinib exposures at the doses tested were 0.8–2.1 fold of those in Western patients. Of 11 patients with evaluable target lesions, three had stable disease (50 mg n = 2; 125 mg n = 1). One patient with lung cancer was treated for 570 days (ongoing at data cut-off).

**Conclusion:** Saracatinib exhibited an acceptable tolerability profile in Japanese patients with advanced solid tumours. The MTD was considered to be 125 mg.

## 1253

## POSTER

### Two-component Messenger RNA-based Vaccines Provide Strong Anti-tumour Effect Especially in Combination With Radiation Therapy

M. Fotin-Mleczek<sup>1</sup>, C. Lorenz<sup>1</sup>, K. Duchardt<sup>1</sup>, K.J. Kallen<sup>1</sup>, S. Huber<sup>2</sup>.  
<sup>1</sup>CureVac GmbH, Research and Development, Tübingen, <sup>2</sup>Universitätsklinikum Tübingen, Department of Radio-Oncology, Tübingen, Germany

**Background:** Complexation of mRNA with the cationic protein protamine generates two-component tumour vaccines with two principle activities: antigen expression and immune stimulation.

Compared to their single components, two-component mRNA vaccines induce superior innate as well as balanced adaptive immune responses: these comprise humoral as well as T cell mediated immunity and include induction of memory T cells. Immunization of mice bearing ovalbumin (Ova) positive E.G7 tumours with a two-component anti-Ova mRNA vaccine mediates a strong anti-tumour response also under therapeutic conditions. Anti-tumour efficacy depends on the size of established tumours at the beginning of treatment.

**Material and Methods:** To test whether a combination of our vaccine with radiotherapy could achieve a therapeutic effect against large, clinical size tumours, mice were inoculated with E.G7 tumour cells and left untreated until the tumours reached a volume of around 200–250 mm<sup>3</sup>. Mice were treated either with immunotherapy alone, radiation alone or combined radioimmunotherapy.

**Results:** Immunotherapy alone was only marginally effective against these large tumours, whereas radiation of the tumours induced transient growth stagnation for about 7 days. However, combined radioimmunotherapy dramatically improved anti-tumour efficacy. All mice treated this way